President and CEO
Dr. Yuxin Chen, who is a professor, doctoral supervisor, academic leader and PhD in biochemistry, graduated from University of Alberta, Department of Biochemistry. He was a post-doctorate fellow in Department of Biochemistry and Molecular Genetics, University of Colorado Denver before back to China. After retuning, he created Jiangsu Pharmaceutical & Biotechnology Co., Ltd. Dr. Chen has been working in the field of antimicrobial peptide and polypeptide medicine for many years. He proposed and compensated the mechanism of action of antimicrobial peptides, published more than 50 research papers included in SCI on international top journals, and declared a number of PCT international patents, American patents, European patent and Chinese patents, and he is the main inventor of ProteLight patents. He won the one hundred Overseas Chinese professionals “Outstanding Entrepreneurship Award” granted by the State Council in 2009, and the team under his leadership own the first “Key Overseas Chinese Entrepreneurial Team” honor granted by the State Council. As the main person in charge of science and technology projects, he has gained supports and rewards added up to 40 million yuan from national, provincial and municipal science and technology funding.
Vice-president of Production
Mr. Wenren Wang, who is a senior engineer, licensed pharmacist, and master in organic chemistry, graduated from Jilin University, department of organic chemistry and got bachelor degree in 1985. He has worked in Jirui Pharmaceutical Co., Ltd. as Vice President, in Xiuzheng Pharmaceutical Group new drug R&D center as Director and in Haoyue Group as Executive Assistant and Director of biochemical production center. He has presided over and participated in dozed of new drug R & D, including national first category new medicine Gatifloxacin’ raw materials and preparations (Trade name is Bi Zhi), national second category new medicine Irbesartan’s raw materials and preparations (Trade name is Ge Ping), national second category new medicine Itopride Hydrochloride’s raw materials and preparations, national second category new medicine Rabeprazole‘s raw materials and preparations, Ibuprofen and Pseudoephednine dispersible tablets(Trade name is Ke Tai shu), and Feining sugar-free particles 5 grams.
Mrs. Mingxia Chen, who is a chief pharmacist, master in pharmacology, graduated from college of pharmacy of Jilin University. With strong comprehensive capacity in clinical and scientific research, she has worked in Beijing Joinn Laboratories and Beijing Hua An Fu Pharmaceutical Research Laboratories, and presided over and participated in multiple pharmacology and toxicology tests, including national first category anti-tumor new drug BCT-100, national first category hemostatic new drug NWK-B, national first category cardiovascular new drug YI YE PIAN, and national first category new drug PL-5, and participated in central laboratory construction. She has been in charge of or participated in 18 patent application, and was main participant in above research projects. With more than 20 years of experience in new drugs preclinical research tests, she is charge of pharmacology and toxicology research, writing of application materials, and execution arrangement of R&D projects.
Chief Technical Consultant
Hartmut Michel, PhD in biochemistry, Nobel Prize winner of chemistry in 1988, academician of German Academy of Sciences, foreign academician of the Royal Society, foreign academician of the Royal Netherlands Academy, and foreign academician of Chinese Academy of Sciences. The top international scientist in membrane polypeptide and membrane protein. He is the president of Institute of Biophysics, Max Planck Institute, and member of The German National Science Council.
Shareholder/Technical Consultant/International Business Consultant
Robert S. Hodges, PhD in biochemistry, academician of Royal Society of Canada, the former president of American Peptide Society, at present he is the director of Biomolecular Structure Center in University of Colorado Denver. With more than 50 years of antimicrobial peptide research experience, he published more than 500 academic papers, applied for more than 70 patents. He is an internationally renowned scientist, his laboratory has very high reputation in science, conscientiousness and advanced technology among similar research field in the world. He had been CEO and Member of the Board of a number of international institutions, and he is one of ProteLight shareholders.
Apart from our own strong technical team, ProteLight has close R & D cooperation with famous research institutes, including Max Planck Institute, University of Colorado, University of British Clumbia, University of Alberta, AMMS (Academy of Military Medical Sciences), Chinese Academy of Medical Science, Peking University, Jilin University, etc.